Form 8-K - Current report:
SEC Accession No. 0000950170-24-090732
Filing Date
2024-08-05
Accepted
2024-08-05 16:05:24
Documents
13
Period of Report
2024-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pstx-20240805.htm   iXBRL 8-K 40987
2 EX-99.1 pstx-ex99_1.htm EX-99.1 129316
3 GRAPHIC img265366334_0.jpg GRAPHIC 25951
  Complete submission text file 0000950170-24-090732.txt   332318

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pstx-20240805.xsd EX-101.SCH 24823
15 EXTRACTED XBRL INSTANCE DOCUMENT pstx-20240805_htm.xml XML 4723
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Filer) CIK: 0001661460 (see all company filings)

EIN.: 472846548 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39376 | Film No.: 241174722
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)